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Methylation Markers for Small Cell Lung Cancer in
Peripheral Blood Leukocyte DNA
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Yanhong Wu, PhD,* Jun Chen, MD, PhD,§ Stephen N. Thibodeau, PhD,* V. Shane Pankratz, PhD,†
and Ping Yang, MD, PhD§
Introduction: Small cell lung cancer (SCLC) is the most aggressive
form of lung malignancy.
Methods: To identify and validate potential DNA methylation
markers for risk assessment and disease detection, we examined
peripheral blood leukocyte DNA specimens for methylation differ-
ences between SCLC cases and controls. We tested 1505 CpG sites
using the Illumina Beadchip assay and validated 9 CpG sites using
pyrosequencing technology.
Results: In 44 matched SCLC case-control pairs, we identified
significant differences at 62 CpG sites (false discovery rate 0.05)
in 52 independent genes. Of those, we further determined 43 sites in
36 genes with a mean methylation level difference greater than 0.03
between the cases and controls. We then selected and validated 9
CpG sites for methylation differences in an independent set of 138
matched case-control pairs. The 9 validated CpG sites predicted a
higher risk for cases than controls in 85.8% of all pairs of cases and
controls, and 2 (in genes CSF3R and ERCC1) jointly contributed
most of the discriminating ability.
Conclusions: Our replicated results demonstrated feasibility of
applying large-scale methylation arrays for biomarker discovery and
subsequent validation in peripheral blood DNA. The CpG sites
identified in this study may potentially assist in risk prediction and
diagnosis of SCLC.
Key Words: Methylation, Biomarker, Small cell lung cancer,
Leukocyte.
(J Thorac Oncol. 2010;5: 778–785)
Small cell lung cancer (SCLC) constitutes approximately13% of all newly diagnosed lung cancers.1 In comparison
with the more common non-small cell lung cancer (NSCLC),
SCLC has more rapid doubling time, higher growth fraction,
earlier development of widespread metastases, and more
dramatic initial response to chemotherapy and radiation.
Despite high initial responses to therapy, most patients die of
recurrent disease. Untreated SCLC has the most aggressive
clinical course of any lung tumor, with a median survival of
only 2 to 4 months after diagnosis.1 Cigarette smoking is the
strongest risk factor for the development of SCLC. Virtually,
all patients with SCLC are current or past smokers, and its
risk is related to the duration and intensity of smoking.2,3
Epigenetics is defined as the study of heritable changes
in gene expression, which occur in the absence of a DNA
sequence change and is believed to be important in the etiology
of common human diseases4,5 including cancer. Increasing ev-
idence has demonstrated that epigenetic modifications may re-
sult from various types of environmental insults and can lead to
cancer development. In a recent review,6 epigenetics is noted to
stand at the epicenter of modern medicine because it unites
nuclear reprogramming during development, environmentally
induced changes in the body, and the cellular response to
external stimuli. Unlike the DNA sequence, epigenetic changes
distinguish one tissue type from another, and environmental
exposures alter the epigenetic program. The ability of genes to
alter their expression is controlled by epigenetic factors such as
DNA methylation.7,8
Differential methylation status in peripheral blood
DNA has been linked to risk of several cancers, although
little is known for lung cancer.9–11 To determine whether
global methylation in DNA derived from peripheral blood, an
easily accessible tissue, is associated with head and neck
squamous cell carcinoma, Hsiung et al9 assessed the LRE1
sequence methylation level in a population-based case-con-
trol study and found that hypomethylation of the sequence led
to a significant 1.6-fold increased risk for the disease. Moore
et al10 reported in a case-control study an association of
leukocyte DNA hypomethylation with increased risk of de-
veloping bladder cancer, independent of smoking and other
assessed risk factors. Currently, Widschwendter et al11 exam-
ined locus-specific methylation and found that particular
methylation patterns in peripheral blood DNA may serve as
surrogate markers for breast cancer risk. Therefore, methyl-
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ation status in peripheral blood DNA specimens may provide
a useful biomarker for disease risk assessment and potential
early detection and differential diagnosis. Because the meth-
ylation status is reversible, further understanding the role of
methylation in disease etiology may facilitate targeted ther-
apy and pave the road for future chemoprevention and arrest-
ing disease progression. In this study, we used an array-based
genomic DNA methylation approach identifying potential
quantitative biomarkers for diagnosis or risk assessment of
SCLC using peripheral blood DNA in a case-control study.
PATIENTS AND METHODS
Sample Recruitment
The methods of identifying and enrolling patients with
SCLC and controls were reported previously.12–14 In brief,
newly diagnosed cases of lung cancer are identified by a daily
electronic pathology reporting system. Once identified, pa-
tients were consented and enrolled, their medical records
were abstracted, and interviews were conducted. Overall
participation and blood sample donation rates were 87% and
73%, respectively. For controls, we selected community res-
idents, identified by having had a general medical examina-
tion and a leftover blood sample from routine clinical tests,
excluding individuals diagnosed with major organ failure
(e.g., heart, brain, lung, kidney, or liver) on or before their
visit. SCLC cases were identified from among all lung cancer
cases, and controls were selected such that the distributions of
age, sex, and smoking history were comparable between the
cases and controls. Ninety-five percent of the study subjects
were white, representing an U.S. Midwestern population in
and surrounding Minnesota. The Mayo Clinic Institutional
Review Board approved this study.
DNA Modification by Sodium Bisulfite
We extracted DNA from 5 mL of whole blood using an
automated platform following QIAGEN kit (Germantown,
MD). Because whole blood DNA was predominantly derived
from leukocytes and freely circulating DNA in whole blood
is negligible, we referred to the whole blood DNA as leuko-
cyte DNA. We modified the genomic DNA specimens using
an EZ DNA methylation kit from Zymo Research Corpora-
tion (Orange, CA) that combined bisulfite conversion and
DNA cleanup. This modification kit is based on the three-step
reaction that takes place between cytosine and sodium bisul-
fite in which cytosine is converted into uracil. We used 1 g
of genomic DNA from peripheral blood DNA for the modi-
fication under recommendation from the manufacturer.
Treated DNA specimens were stored at 20°C and were
assayed within 2 weeks.
Methylation Profiling Analysis
We labeled and hybridized the modified DNA speci-
mens with equal numbers of samples from each group,
balanced across the entire Beadchip, to avoid confounding
study results with processing variance. We imaged the arrays
using a BeadArray Reader scanner, which represented each
methylation data point as fluorescent signals from the M (meth-
ylated) and U (unmethylated) alleles. The proportion methylated
( value) at each CpG site was calculated using BeadStudio
Software (Illumina Inc., San Diego, CA), after subtracting
background intensity, computed from negative controls, from
each analytical data point.
Pyrosequencing Methylation Assays
Primers were designed using Pyrosequencing Assay
Design Software (Biotage AB, Uppsala, Sweden). Se-
quences of the primers are listed in Table 1. The polymer-
ase chain reaction was carried out on 10 ng of bisulfite-
treated DNA using TaqGold DNA polymerase (Applied
Biosystems, Foster City, CA) under the following condi-
tions: 10 minutes at 95°C, followed by 50 cycles of 35
seconds at 95°C, 35 seconds at 57.5°C, and 1 minute at 72°C.
Pyrosequencing reactions were performed on Biotage Pyro-
Mark MD System (Biotage AB) according to the manufac-
turer’s protocols by the sequential addition of single nucleo-
tides in a predefined order. Raw data were analyzed using
Pyro Q-CpG 1.0.9 analysis software (Biotage AB). The CpG
methylation level (ranging from 0 to 1) was represented by
the percentage of methylated C among the sum of methylated
and unmethylated C.
Data Analysis
We summarized and compared demographic character-
istics between cases and controls using 2 tests for nominal
variables or rank sum tests for the quantitative variables. We
also summarized the percent methylated measurements by
their mean and standard deviation within the two study
groups and used analysis of covariance approaches to com-
pare the degree of methylation between study groups for each
CpG site while adjusting for pack-years of smoking. Because
of the non-normality of the methylation values, we used
rank-based analyses, which are analogous to rank-sum tests
when there are no covariates. After obtaining the p values for
each of the CpG sites in the testing set, we used false
discovery rate (FDR) approaches and computed a q value for
each p value.15 CpG sites with q values of less than 0.05 were
considered to be significant.
In the validation phase, we compared the methylation
levels of the 10 selected CpGs between the cases and controls
in the validation set using the rank-based procedures outlined
earlier. We also used logistic regression approaches to simul-
taneously assess the association between all nine validation
CpGs and case-control status. We further refined this multi-
variable model by a stepwise model selection with the p value
to enter and remain in the model set at 0.05 to determine a
CpG set that simultaneously contributes to the discrimination
between SCLC cases and controls. As part of these logistic
regression analyses, we measured the degree of concordance
between model predictions and observed case-control status
by extracting estimates of the area under the receiver oper-
ating characteristic curve. This quantity, often referred to as
the c-statistic, examines all possible case-control pairs and
measures the proportion of the time the statistical model
predicts higher risk for the case.16 All analyses were con-
ducted using the SAS software system (Cary, NC).
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RESULTS
Characteristics of Study Subjects
By matching design, no difference in age, sex, and
smoking status was found between the cases and controls in
both the testing and validation sets. Basic descriptive infor-
mation of the cases and controls are provided in Table 2. For
the testing set, five cases were dropped because of DNA
quality issues, and the remaining 39 cases and 44 controls
were used in the analysis. There was a greater than 3-year
difference between the cases and controls in the mean pack-
years of cigarette smoking (60.1 versus 56.5). However,
median pack-years were similar (51 versus 52), and the test
comparing the two groups did not reach statistical signifi-
cance (p  0.525). To be conservative, the number of
pack-years was adjusted in all DNA methylation analyses.
Differentially Methylated CpG Sites
Because the majority of the patients with SCLC re-
ceived radiation treatment or chemotherapy before blood was
drawn, we examined the correlations between the time on
treatment (as a proxy for treatment intensity) and the degree
of methylation to determine whether the CpG methylation
levels might be affected by treatment in the 39 patients with
SCLC. Among the 1505 CpG sites, we found that the length
of time on treatment was significantly correlated with the
methylation levels of 173 CpGs (p  0.05). Although some
of these associations may be false-positives, to be conserva-
tive, we excluded all 173 CpGs from the analyses. Among the
remaining 1332 CpG sites, 922 were located within CpG
islands and 410 were in non-CpG islands. We observed
significant differences between SCLC cases and controls at
62 sites in 52 independent genes (FDR 0.05). Interestingly,
only 25 of the 62 sites were in CpG islands, which was
significantly lower than the expected 42.9 sites (62  922/
1332) (p  0.001, 2 test). The odds of a significant CpG not
being in a CpG island was greater than three times higher
than the odds of being in a CpG island (OR  3.56, 95%
confidence interval [CI]: 2.11–6.00). Furthermore, only 6 of
the 62 sites showed an increased level of methylation in
patients with SCLC, including 2 in the ITK gene, 2 in the
RUNX3 gene, 1 in each of the CTLA4 and PLG genes.
Because some methylation differences were small and diffi-
cult to reliably detect, we further excluded the CpG sites with
an absolute mean  difference of less than 0.03, resulting in
43 significant CpG sites of primary interest in 36 independent
genes (Table 3).
TABLE 1. Primers for Pyrosequencing Methylation Assay
Genes Primer Names Notes Primer Sequences (From 5 to 3)
PECAM1 PECAM1f PCR-forward, biotin-labeled TTGAGAAATTAGTTTTGTGAAAAG
PECAM1r PCR-reverse TCAAACCAACCCAAACCCCATTATT
PECAM1sr Sequencing-reverse TTCCAACCATAACTACCATTACCT
S100A2 S100A2f PCR-forward GTTAGTTTTATTATTAGTTGGGGGAGGGT
S100A2r PCR-reverse, biotin-labeled ACCCCCATCCAAAATACCC
S100A2sf Sequencing-forward GGAAGTGGGAGGTGT
ERCC1 ERCC1f PCR-forward GAGTTAGTGTTGGTGATATAGTAGTGA
ERCC1r PCR-reverse, biotin-labeled CATCCCAAACCTACCCATTCT
ERCC1sf Sequencing-forward TTAAGGTTTAGTAAGGGATATAGATA
SLC22A18 SLC22A18f PCR-forward GTGTTTATTTTTAAGATTGGTTGAGGTATT
SLC22A18r PCR-reverse, biotin-labeled TCCCCAACCCCAAAACATT
SLC22A18sf Sequencing-forward TTAGTTAGTTTGGATTTTTTTAT
CSF3R CSF3Rf PCR-forward, biotin-labeled GGGTGTGTTTTAGGTTTTAGGGAATT
CSF3Rr PCR-reverse CCCAAAATTCCTATTTCTCCATCTA
CSF3Rsr Sequencing-reverse CCTAATCTATAAACAATACACAAA
MMP9 MMP9f2 PCR-forward GTTTGGGGTTTTGTTTGATTTG
MMP9r2 PCR-reverse, biotin-labeled CCACCCCTCCTTAACAAACAAATAC
MMP9seqf2 Sequencing-forward TGATTTGGTAGTGGAGAT
EMR3 EMR3f2 PCR-forward ATTTTAGGTTAGTTGATTTATGAAAT
EMR3r2 PCR-reverse, biotin-labeled AAATTTACCAACTCAATCATCCCAAAA
EMR3seqf2 Sequencing-forward GAAAAGTAAATTGTTTTTTTTTTTT
IL-10 IL-10-f1 PCR-forward TGTAAGTTTAGGGAGGTTTTTTTATTTATT
IL-10-r1 PCR-reverse, biotin-labeled AATTCATATTCAACCAATCATTTTTACTT
IL-10-seqf1 Sequencing-forward AAGTTATAATTAAGGTTTTT
CAV1 CAV1f3 PCR-forward AAGGGAAGGTTTAGGATAGGGTAGGATT
CAV1r3 PCR-reverse, biotin-labeled TTTTCCCAATACATCATCTCAACA
CAV1seqfs3 Sequencing-forward AGGGTAGGATTGTGGAT
TRIP6 TRIP6f2 PCR-forward GGGTAGGGGTTGGGGAATT
TRIP6r2 PCR-reverse, biotin-labeled ATACCCCCCCCCTACTAAACCC
TRIP6s2 Sequencing-forward GAAGGGGATTTTGTGA
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Validation of Selected CpG Sites by
Pyrosequencing Methylation Assay
Based on three major parameters (FDR q values, num-
ber of significant CpGs/gene, and mean difference between
groups), we selected 10 CpG sites including 9 significant
CpGs (FDR 0.05) for validation and 1 nonsignificant CpG
(FDR 0.05). These CpG sites were located in 10 different
genes (IL10, PECAM1, S100A2, MMP9, ERCC1, EMR3,
SLC22A18, TRIP6, CSF3R, and CAV1), with CAV1 serving
as a negative control. We designed a new assay for each of
the 10 CpG sites using pyrosequencing technology.17,18 Fig-
ure 1 shows methylation levels of a CpG site, 85bp upstream
to the transcription start site in the gene, IL10, in three
different samples.
We then tested the 10 CpG sites for methylation dif-
ferences, again in peripheral blood DNA specimens from a
validation set between 138 SCLC cases and 138 matched
controls (Table 2, right panel). The nine testing-set-positive
CpG sites again demonstrated significant differences (all p
values 0.0003, Table 4), whereas the negative control CpG
site only differed between the validation set of the cases and
controls in an absolute percent methylated by less than 1%.
This small difference did not reach statistical significance.
CpG Methylation Patterns and Risk Prediction
of SCLC Using Logistic Regression Models
Based on the nine validated CpG sites accounting for
age, sex, and smoking history, our model had an area under
the receiver operating characteristic curve of 0.858 (Figure
2), suggesting the model correctly classified SCLC cases as
being at a higher risk than controls for 85.8% of case-control
pairs. Further stepwise selection identified two of the nine
sites, one in CSF3R and the other in ERCC1, contributing
independent information to discriminate cases from controls.
Specifically, for each 5% decrease in the methylation level of
ERCC1, there was an approximately 4-fold (OR  3.9, 95%
CI: 2.0–6.1, p  0.001) increase in the odds ratio of SCLC;
for each 5% methylation decrease of CSF3R, there was a
1.5-fold higher OR of SCLC (OR  1.5, 95% CI: 1.1–2.0,
p  0.008).
DISCUSSION
In applying newly developed methylation BeadChip
technology, we performed methylation profiling analysis of
1505 tested CpG sites in 807 genes and identified 62 CpGs
whose methylation status were significantly associated with
SCLC. Forty-three of these 62 had an absolute mean differ-
ence greater than 0.03 between the cases and controls, and 9
of these were further confirmed using pyrosequencing meth-
ylation assays in additional cases and controls. These results
suggest that methylation status of peripheral blood DNA, a
stable and easily accessible material, might be reliably used
for risk assessment and diagnosis of SCLC.
Among the nine validated genes, at least five were
reported to be associated with lung cancer. For example, the
IL10 expression by tumor-associated macrophages showed a
significant role in the progression and prognosis of NSCLC.19
Patients whose tumors had a positive S100A2 expression had
a significantly lower overall survival and disease-specific
survival rate.20 Another study showed S100A2 being up-
regulated in an early stage of patients with NSCLC, indicat-
ing its important role for molecular diagnosis of NSCLC at an
early stage; therefore, prognostically more favorable.21 High
ERCC1 expression was associated with short survival.22,23
Interestingly, results of these studies came from cancer tis-
sues and were consistent with our findings from peripheral
blood DNA, indirectly supporting that hypomethylation of
TABLE 2. Characteristics of Patients with SCLC and Healthy Controls












(N  276) p
Age 0.5392 0.6736
Mean (SD) 64.8 (6.1) 65.6 (5.7) 65.2 (5.8) 64.4 (9.54) 64.8 (9.46) 64.6 (9.48)
Median 65.0 65.5 65.0 66.0 66.0 66.0
Q1, Q3 61.0, 69.0 61.5, 69.0 61.0, 69.0 59.0, 71.0 59.0, 71.0 59.0, 71.0
Range 54.0–78.0 57.0–78.0 54.0–78.0 37.0–85.0 33.0–82.0 33.0–85.0
Gender 0.6470 1
Female 17 (43.6%) 17 (38.6%) 34 (41.0%) 61 (44.2%) 61 (44.2%) 122 (44.2%)
Male 22 (56.4%) 27 (61.4%) 49 (59.0%) 77 (55.8%) 77 (55.8%) 154 (55.8%)
Smoking status 0.9072 1
Never 0 0 0 8 (5.8%) 8 (5.8%) 16 (5.8%)
Former 20 (51.3%) 22 (50.0%) 42 (50.6%) 63 (45.7%) 63 (45.7%) 126 (45.7%)
Current 19 (48.7%) 22 (50.0%) 41 (49.4%) 67 (48.6%) 67 (48.6%) 134 (48.6%)
Pack-years 0.5249 0.9218
Mean (SD) 60.1 (25.1) 56.5 (25.8) 58.2 (25.4) 56.8 (29.4) 56.4 (29.2) 56.6 (29.3)
Median 51.0 52.0 52.0 52.0 52.0 52.0
Q1, Q3 42.0, 74.0 39.0, 68.3 41.0, 72.0 37.0, 75.0 36.0, 77.0 36.0, 76.5
Range 22.0–126.0 17.0–141.0 17.0–141.0 3.0–146.0 3.0–147.0 3.0–147.0
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these genes may increase gene expression. To date, it is not
known whether the abnormal methylation in peripheral blood
DNA from patients with SCLC is inherited or acquired.
Further investigation is clearly needed.
Imprinting genes in peripheral blood leukocytes may
also serve as an indicator of cancer risk.24 In this study, we
observed an imprinting gene, SLC22A18, whose methylation
levels in the tested CpG demonstrated a strong association
with SCLC in both the testing and validation sets (adjusted
p  0.0001, Tables 3 and 4). The gene is located in the
imprinted gene domain of 11p15.5, an important tumor-
suppressor gene region; alterations in this region have been
associated with the Beckwith-Wiedemann syndrome and
multiple malignancies including lung cancer.25–27 The finding
TABLE 3. Differential Methylations Between 39 SCLC Cases and 44 Healthy Controls in Testing Set
Symbol Illumina CpG IDa CpG Island Adjusted p q
Controls Cases
Case/Control
DifferenceMean  SD Mean  SD
SLC22A18 SLC22A18_P216_R No 0.00002 0.00877 0.464 0.091 0.354 0.131 0.11
PADI4 PADI4_E24_F No 0.00002 0.00877 0.257 0.067 0.190 0.096 0.067
MMP9 MMP9_P189_F No 0.00005 0.00877 0.377 0.076 0.298 0.100 0.079
LTB4R LTB4R_P163_F No 0.00005 0.00877 0.303 0.063 0.242 0.068 0.061
S100A2 S100A2_E36_R No 0.00006 0.00877 0.353 0.070 0.282 0.073 0.071
RUNX3 RUNX3_P247_F Yes 0.00006 0.00877 0.703 0.102 0.790 0.153 0.087
MPO MPO_E302_R No 0.00007 0.00877 0.700 0.065 0.618 0.089 0.082
IL10 IL10_P85_F No 0.00007 0.00877 0.229 0.051 0.178 0.076 0.051
RUNX3 RUNX3_E27_R No 0.00008 0.00885 0.862 0.049 0.900 0.092 0.038
PECAM1 PECAM1_E32_R Yes 0.00008 0.00885 0.257 0.065 0.189 0.087 0.068
EMR3 EMR3_E61_F No 0.00014 0.01292 0.22 0.049 0.166 0.085 0.054
SPI1 SPI1_E205_F Yes 0.00017 0.01292 0.315 0.057 0.250 0.100 0.065
TNFRSF1A TNFRSF1A_P678_F No 0.00019 0.01292 0.754 0.070 0.662 0.125 0.092
LMO2 LMO2_E148_F No 0.00019 0.01292 0.442 0.103 0.327 0.151 0.115
IL10 IL10_P348_F No 0.0002 0.01292 0.64 0.086 0.509 0.180 0.131
ERCC1 ERCC1_P440_R Yes 0.0002 0.01292 0.141 0.046 0.103 0.047 0.038
CSF3R CSF3R_P472_F No 0.00041 0.02392 0.371 0.097 0.276 0.134 0.095
JAK3 JAK3_P1075_R No 0.00044 0.02392 0.683 0.077 0.617 0.087 0.066
LCN2 LCN2_P141_R No 0.00048 0.02392 0.789 0.078 0.708 0.131 0.081
CD82 CD82_P557_R Yes 0.00048 0.02392 0.277 0.097 0.192 0.109 0.085
PI3 PI3_P274_R No 0.00052 0.02457 0.835 0.053 0.763 0.110 0.072
TRIP6 TRIP6_P1090_F Yes 0.00053 0.02457 0.359 0.107 0.259 0.139 0.100
TIE1 TIE1_E66_R No 0.00055 0.02457 0.224 0.067 0.164 0.085 0.06
TRIP6 TRIP6_P1274_R Yes 0.00061 0.02543 0.617 0.101 0.488 0.178 0.129
CD9 CD9_P585_R Yes 0.00063 0.02548 0.385 0.061 0.314 0.103 0.071
SEPT9 SEPT9_P374_F Yes 0.00065 0.02555 0.252 0.097 0.180 0.102 0.072
MPL MPL_P62_F No 0.00091 0.0319 0.492 0.098 0.389 0.151 0.103
CASP10 CASP10_P334_F No 0.00094 0.0319 0.243 0.059 0.191 0.078 0.052
AIM2 AIM2_P624_F No 0.00094 0.0319 0.467 0.137 0.353 0.178 0.114
SEPT9 SEPT9_P58_R Yes 0.001 0.03234 0.929 0.046 0.888 0.061 0.041
CSF1R CSF1R_E26_F No 0.00107 0.03239 0.749 0.075 0.662 0.135 0.087
CSF3R CSF3R_P8_F No 0.0013 0.03635 0.225 0.072 0.168 0.096 0.057
MMP14 MMP14_P13_F Yes 0.00167 0.04137 0.500 0.101 0.400 0.157 0.100
BTK BTK_P105_F No 0.00167 0.04137 0.132 0.047 0.100 0.050 0.032
GRB7 GRB7_E71_R No 0.00178 0.04319 0.374 0.092 0.296 0.134 0.078
STAT5A STAT5A_P704_R No 0.00189 0.04428 0.183 0.06 0.139 0.059 0.044
NOTCH4 NOTCH4_E4_F No 0.00189 0.04428 0.170 0.069 0.123 0.072 0.047
HOXB2 HOXB2_P99_F Yes 0.00214 0.04667 0.552 0.09 0.483 0.103 0.069
MFAP4 MFAP4_P197_F No 0.0022 0.04721 0.244 0.061 0.196 0.080 0.048
SLC5A5 SLC5A5_E60_F Yes 0.00227 0.04721 0.527 0.089 0.459 0.107 0.068
CD34 CD34_P339_R No 0.00227 0.04721 0.268 0.049 0.236 0.056 0.032
MFAP4 MFAP4_P10_R No 0.00249 0.04933 0.172 0.061 0.133 0.059 0.039
EMR3 EMR3_P39_R No 0.00264 0.04933 0.287 0.064 0.232 0.072 0.055
CAV1 CAV1_P169_Fb Yes 0.35439 0.63028 0.191 0.056 0.176 0.054 0.015
a The CpG IDs in bold are selected to run pyrosequencing for validation. The CpG site in the gene CAV1 was selected as negative control. SD, standard deviation.
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that the SLC22A18methylation level is associated with SCLC
further demonstrates the importance of the imprinting region
in cancer etiology.
Global hypomethylation has been reported in cancer
tissues (somatic) and constitutive tissues (germline).9,10,28–30
Lack of DNA methylation at specific CpG sites has also been
reported recently to be associated with breast cancer risk.11
Of the 62 CpG sites that were identified in this study, 56 are
hypomethylated and only 6 are hypermethylated. The hypom-
ethylation may be caused by different mechanisms. First,
tumor formation requires activation of oncogenes and tumor
response genes, which can be achieved through promoter
hypomethylation of related genes. Second, this hypomethy-
lation may be part of global hypomethylation commonly seen
in cancer patients and may be not associated with activation
of any specific genes. The fact that methylation changes pref-
erentially occur in non-CpG islands indirectly support this pos-
sibility. If global hypomethylation causes genomic instability29
FIGURE 1. Methylation analysis of IL10_P85_F CpG by pyrosequencing technology. Methylation analysis of IL10_P85_F CpG
in three representative samples by pyrosequencing technology. The first arrow at the T position indicates signal peak of un-
methylated C. The second arrow at the C position represents signal peak of methylated C. The CpG methylation level is the
percentage of methylated C among the sum of methylated C and unmethylated C. The methylation levels for the samples 1,
2, and 3 are 2%, 21%, and 82%, respectively.
TABLE 4. Differential Methylations Between 138 SCLC Cases and 138 Matched Controls: Validation Study
Gene








IL10 IL10_P85_F No 0.0001 0.116 0.032 0.077 0.035 0.039
PECAM1 PECAM1_E32_R Yes 0.0001 0.343 0.089 0.242 0.104 0.101
S100A2 S100A2_E36_R No 0.0001 0.288 0.076 0.211 0.063 0.077
MMP9 MMP9_P189_F No 0.0001 0.058 0.020 0.037 0.021 0.021
ERCC1 ERCC1_P440_R Yes 0.0001 0.135 0.044 0.085 0.037 0.050
EMR3 EMR3_E61_F No 0.0001 0.161 0.043 0.115 0.050 0.046
SLC22A18 SLC22A18_P216_R No 0.0001 0.227 0.059 0.155 0.074 0.072
TRIP6 TRIP6_P1090_F Yes 0.0003 0.44 0.255 0.319 0.259 0.121
CSF3R CSF3R_P472_F No 0.0001 0.277 0.066 0.18 0.084 0.097
CAV1 CAV1_P169_F Yes 0.3577 0.1 0.063 0.109 0.07 0.009
SD, standard deviation.
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and hence increases risk to cancer, the current finding from
peripheral blood DNA may represent, at least in part, constitu-
tive hypomethylation of patients with SCLC and explain why
these individuals are susceptible to developing cancer.
Among the six hypermethylated CpG sites, two are
from the gene RUNX3. The gene, a tumor suppressor, is
inactivated in a variety of cancers including SCLC.31–34 The
promoter hypermethylation of the gene is believed to be a
major mechanism for the gene inactivation in tumor tissues.
One of the two CpG sites (RUNX3_P247_F) is located within
a CpG island (promoter region) and shows an 8.72% differ-
ence between SCLC cases and controls. Although not tested,
we predict a lower activity of RUNX3 in peripheral blood
leukocytes of patients with SCLC. If reduced activity of the
gene is also seen in lung tissue, it may be responsible for the
increased risk of SCLC.
However, this study has some limitations. First, we
were unable to determine what mechanisms caused the dif-
ferential methylation between the cases and controls. The
possible mechanisms include differences in genetics, treat-
ment, nutritional status, and subpopulation of leukocytes. A
comprehensive analysis that addresses these potential mech-
anisms will be necessary for future study. Second, we tested
only one to two CpG sites per gene that are predefined by the
manufacturer for inclusion on the methylation array that we
used (Illumina Inc.). The tested CpGs are not necessarily
most representative for a particular gene. More detailed
analysis is needed to fully cover all CpGs in related genes.
Nevertheless, our results demonstrate methylation differences
between patients with SCLC and controls are present and can
be reliably detected in peripheral blood leukocyte DNA.
SCLC is traditionally not treated with surgical resection; thus,
it is difficult to obtain adequate tissue samples for molecular
analysis. DNA from peripheral blood leukocytes has been
widely used in genetic analysis. The successful use of the
easily accessible specimen in this study will significantly
expand the research application from genetics (such as ge-
nome-wide association studies) to epigenetics (such as epig-
enome-wide association studies). We believe that our meth-
ylation panel is potentially useful as a second-tier disease
prediction and a noninvasive detection tool among high-risk
individuals, particularly smokers with equivocal findings
from computed tomography screening.
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